Online ISSN: 2515-8260

Keywords : Dapagliflozin

Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients

Dr. Pushkar Mani, Dr. Anusha Vohra, Dr. Shipra Jain, Dr Chandrabhan, Dr. Ruchi Mathur

European Journal of Molecular & Clinical Medicine, 2023, Volume 10, Issue 1, Pages 3949-3956

Type 2 Diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia. It affects millions of people worldwide and is the fourth leading cause of death in India. One of the most important and effective treatment to achieve glycemic control in diabetic patients are various oral hypoglycemic agents with adequate lifestyle modifications and physical activities. Sodium glucose cotransporter 2 inhibitors are one such emerging oral hypoglycemic agents that achieve the desired goal with some complimentary benefits. This prospective observational study using four different SGLT2 inhibitors amongst 68 patients with Type II diabetes namely Canagliflozin 100 mg, Dapagliflozin 10 mg, Empagliflozin 25 mg, Remogliflozin 100mg has shown promising results in managing glycemic control along with complimentary benefits including weight loss